The present disclosure relates generally to a drug delivery safety device having a passive trigger activation system, i.e., structure for activation of the trigger which is engaged upon use of the drug delivery device to provide post-injection needle shielding without additional intervention by the user.
Accidental needle sticks with a used needle can transmit disease. As a result, most prior art needle assemblies have a needle shield. Some prior art needle shields define a rigid sleeve that is manually telescoped or rotated over a needle cannula after use. This procedure often requires the healthcare worker to hold the syringe barrel in one hand and the shield in the other. Because some medical procedures require the application of pressure to the penetration site after the needle has been removed, healthcare workers are often unable to use both hands for shielding the needle cannula. In these situations, workers will deposit the used medical implement on a nearby surface with the intention of shielding the used needle at a more convenient time. However, until the needle is shielded or properly disposed of, it presents a potential danger to other people.
As a further risk to healthcare workers, the additional post-injection activity required to manually shield a used needle, regardless of whether the procedure requires one hand or both hands, increases the likelihood of an accidental needle stick. There is therefore a need for needle shielding systems and devices which are triggered automatically upon use of the needle to treat a patient, thus avoiding any need for the healthcare worker to take extra steps or further handle the medical device to achieve safe shielding of the used needle. Such automatic shielding devices and mechanisms are often referred to as passive medical safety devices or passive shielding systems. In particular, there is a need for passive needle safety devices which require lower force to trigger the shielding mechanism.
A first aspect pertains to a drug delivery safety device comprising a body attached to a needle hub. The body encloses a rotating cam engaged in a slot through a sidewall of the body. The slot comprises three segments: a proximal angled lead ramp, a ledge at the distal end of the angled lead ramp for seating the rotating cam, and an axial slot portion distal to the ledge. The needle hub includes a needle cannula which is surrounded by a flexible housing. The flexible housing connects the body to a lock clip near the distal end of the needle cannula such that the needle cannula is substantially covered by the flexible housing but the distal tip of the cannula is exposed. The passive shielding system is activated by a trigger mechanism comprising a first spring which connects the rotating cam to the lock clip and a second spring in the body extending from the rotating cam proximally toward the needle hub. The first spring biases the lock clip distally and the second spring biases the rotating cam distally. The force applied to the rotating cam by the second spring is sufficient to seat the rotating cam on the ledge of the slot and to maintain its seated position prior to use of the cannula for injection.
In one or more embodiments, the first spring may surround the needle cannula within the flexible housing.
In one or more embodiments, the lock clip may be housed in a cap which is attached to the flexible housing, the cap including an aperture to permit the cannula to pass therethrough.
When the drug delivery safety device is attached to a syringe and used for injection, a proximally-directed force greater than the distally-directed force of the second spring is applied to the lock clip. Thus, the first spring is compressed, and the flexible housing retracts proximally. The proximal force also moves the lock clip proximally along the shaft of the cannula. This proximal force is typically applied when the exposed tip of the needle cannula is inserted into the skin of a patient to the desired depth for administering an injection. The proximal force overcomes the biasing force of the second spring to move the rotating cam in a proximal direction, off of the ledge and down the angled lead ramp. The angled surface of the angled lead ramp causes the rotating cam to rotate as it moves to the proximal end of the angled lead ramp. When the proximal force is subsequently decreased (as when the needle cannula is removed from the patient's skin after completion of the injection) the first spring decompresses, allowing the second spring to again apply sufficient distal force to the rotated rotating cam to move it distally along the axial slot portion. This force moves the lock clip in a distal direction past the distal tip of the needle cannula to cover the distal tip.
In one or more embodiments, the needle hub of the drug delivery safety device may be attached to the barrel of a syringe.
In one or more embodiments, the flexible housing may be a spring coil, a butterfly spring, a zig-zag coil or a rolled-sheet coil. In one or more embodiments, the flexible housing may have slack when in the pre-injection extended position that permits further extension of the flexible housing post-injection to permit the lock clip to cover the distal tip of the needle cannula.
In one or more embodiments, instead of two independent springs, the first and second springs may be composed of a single spring that is fed through the rotating cam.
In one or more embodiments, there are at least two slots in the body. In one or more embodiments, there are two slots in the body on opposite sides of the body.
In one or more embodiments, the lock clip may be a hook clip which contacts the shaft of the needle cannula near the distal end and slides proximally along its length as the needle cannula is inserted into the patient's skin and the first spring is compressed. During the passive shielding portion of the procedure (after removal of the needle cannula from the patient's skin), the hook clip moves distally along the needle cannula and past the distal tip so that the hook portion of the hook clip covers the distal tip.
In one or more embodiments, the lock clip may be comprised of two pieces, one on each side of the needle cannula and each having a contact point with the needle cannula surface. This lock clip functions in the passive drug delivery safety device as discussed above with respect to the hook clip, except that when the two-piece clip moves distally past the distal tip of the needle cannula, the two pieces close together to cover the distal tip.
In one or more embodiments, the drug delivery safety device may further comprise a removable sleeve which fits over the body to prevent triggering of the trigger mechanism. This feature allows the device to be used to fill a syringe prior to injection without activating the passive shielding system. The removable sleeve is removed after filling of the syringe so that the passive shielding system becomes available for triggering when used to administer an injection. In one embodiment, the anti-triggering sleeve fits over the body and includes an interior surface having a protrusion (e.g., a ridge) which engages the axial slot portion of the slot, thereby preventing movement and rotation of the rotating cam.
The anti-triggering system may further comprise a cap which is a removable fill cap covering the exposed tip of the needle cannula. Prior to filling, both the anti-triggering cap and the fill cap may be present on the device. To fill a syringe, the fill cap is removed. Because of the presence of the anti-triggering sleeve, a syringe can be filled multiple times without triggering the passive safety mechanism. If it is desired to transport the filled syringe or delay injection, the fill cap can optionally be re-attached. When it is desired to administer an injection, the anti-triggering sleeve is removed (with the fill cap, if present) to permit movement and rotation of the rotating cam.
A second aspect pertains to a drug delivery safety device comprising a trigger mechanism connecting a needle hub to a lock clip near the distal end of the needle cannula. A flexible housing surrounds the needle cannula and connects the needle hub to the lock clip such that the needle cannula is substantially covered by the flexible housing but the distal tip of the cannula is exposed. The passive shielding system is activated by a trigger mechanism comprising a spring which connects the needle hub to the lock clip. The device also includes a body which engages the needle hub. The body has an inner cavity with proximal and distal ends, and a Y-clip disposed in the inner cavity. First and second arms of the Y-clip are held open by engagement with first and second pockets at the distal end of the inner cavity as well as by distal force exerted by the spring which biases the first and second arms toward the “splayed” or “open” position. The first and second arms of the Y-clip have angled surfaces so that when they are moved toward each other (inwardly or toward a “closed” position) an axial vector force is created. In one or more embodiments the Y-clip may include at least two protrusions which function as travel stops to prevent the Y-clip from leaving the body, thus setting the distance of distal travel of the lock clip.
In one or more embodiments, the spring may surround the needle cannula within the flexible housing.
In one or more embodiments, the lock clip may be housed in a cap which is attached to the flexible housing, the cap including an aperture to permit the cannula to pass therethrough.
When the drug delivery safety device is used to administer an injection, a proximally-directed force applied to the lock clip compresses the spring distally. Compression of the spring retracts the flexible housing in a proximal direction and also moves the lock clip proximally along the needle cannula to expose more of the distal end of the needle cannula. This proximal force is typically applied when the exposed tip of the needle cannula is inserted into the skin of a patient to the desired depth for administering an injection. The proximal force of the compressed spring creates slack in the flexible housing, which allows the Y-clip to move proximally within the body to release the first and second arms from the first and second pockets of the body, and allows the first and second arms to move inwardly toward each other, creating an axial vector force. When the proximal force is subsequently decreased (as when the needle cannula is removed from the patient's skin after completion of the injection) the spring decompresses, and the axial vector force moves the lock clip distally past the distal tip of the needle cannula to cover the distal tip.
In one or more embodiments, the needle hub of the drug delivery safety device may be attached to the barrel of a syringe.
In one or more embodiments, the flexible housing may be a spring coil, a butterfly spring, a zig-zag coil or a rolled-sheet coil. In one or more embodiments, the flexible housing may have slack when in the pre-injection extended position that permits further extension of the flexible housing post-injection to permit the lock clip to cover the distal tip of the needle cannula.
In one or more embodiments, the lock clip may be a hook clip which contacts the needle cannula near the distal end and slides proximally along its length as the needle cannula is inserted into the patient's skin, compressing the spring. During the passive shielding portion of the procedure (after removal of the needle cannula from the patient's skin), the hook clip moves distally along the needle cannula and past the distal tip so that the hook covers the distal tip.
In one or more embodiments, the lock clip may be comprised of two pieces, one on each side of the needle cannula and each having a contact point with the shaft of the needle cannula. This lock clip functions in the passive drug delivery safety device as discussed above with respect to the hook clip, except that when the two-piece clip moves distally past the distal tip of the needle cannula, the two pieces close together to cover the distal tip.
In one or more embodiments, the drug delivery safety device may further comprise a removable anti-triggering cap which fits over the body and prevents triggering of the trigger mechanism. This feature allows the device to be used to fill a syringe prior to injection without activating the passive shielding system. The removable anti-triggering cap is removed after filling of the syringe so that the passive shielding system becomes available for triggering when used to administer an injection. In one embodiment the cap may have an outer wall which fits over the exterior wall of the body and an interior wall which is positioned between the first and second legs of the Y-clip when the cap is placed over the body. The position of the interior wall between the first and second arms keeps the arms “splayed” or “open” even when the spring is compressed, thus preventing release of the first and second arms from the first and second pockets when proximal force is applied.
The anti-triggering system may further comprise a second cap which is a removable fill cap covering the exposed tip of the needle cannula. Prior to filling, both the anti-triggering cap and the fill cap are present on the device. To fill a syringe, the fill cap is removed. Because of the presence of the anti-triggering cap, the syringe can be filled multiple times without triggering the passive safety mechanism. If it is desired to transport the filled syringe or delay injection, the fill cap can optionally be re-attached. When it is desired to administer an injection, the anti-triggering cap is removed (with the fill cap, if present) to permit movement of the arms of the Y-clip.
A third aspect pertains to a drug delivery safety device comprising a needle hub with a needle cannula, and at least two flexible arms axially adjacent to the needle cannula connecting a trigger housing near the distal end of the cannula to the needle hub. The trigger housing includes an aperture in the distal wall which permits the needle cannula to pass therethrough. A trigger mechanism inside the trigger housing is comprised of a spring connecting the trigger housing to the flexible arms, and a double leaf spring lock clip. The lock clip is positioned near the distal end of the needle cannula, such that the tip of the needle cannula is exposed through an aperture in the lock clip. A first leaf of the lock clip removably engages the flexible arms and a second leaf of the lock clip engages the trigger housing. The second leaf of the lock clip includes a distal needle tip cover which, prior to triggering, is in contact with the needle cannula near its distal end, thus keeping the needle tip cover out of alignment with the apertures of the trigger housing and the lock clip. Prior to use for administering an injection, the spring biases the trigger housing and the lock clip in the distal direction, preventing proximal movement of the trigger housing and the lock clip along the shaft of the needle cannula, and maintaining engagement of the first leaf of the lock clip with the flexible arms.
In one or more embodiments, the needle hub of the drug delivery safety device may be attached to the barrel of a syringe by attachment of the needle hub to the collar of the syringe barrel.
In one or more embodiments, the spring may be a spring coil or a leaf spring.
In one or more embodiments, the trigger housing may be configured to fit over an end-cap connecting the at least two flexible arms. The end-cap includes an aperture aligned with the apertures of the trigger housing and the lock clip, permitting the needle cannula to pass therethrough. In one or more embodiments, the end-cap may be integrally molded with the at least two flexible arms.
In one or more embodiments, the spring may surround the end-cap and, prior to use, be biased against the distal interior wall of the trigger housing, thereby forcing the trigger housing and lock clip distally to maintain engagement of the first leaf of the lock clip with the at least two flexible arms.
In one or more embodiments, the first leaf of the lock clip may removably engage the at least two arms by removable engagement with the end-cap, e.g., by means of a proximal hook on the first leaf which engages a shelf on the end-cap.
When the drug delivery safety device is used to administer an injection, a distally-directed force applied to the trigger housing compresses the spring, moving the trigger housing and the lock clip proximally toward the at least two flexible arms. This movement allows the first leaf of the lock clip to disengage from the end-cap. Tension released from the first leaf of the lock clip allows it to flex to an unloaded state, thus maintaining the disengaged position during continued proximal movement of the trigger housing. After disengagement, the needle can be inserted to the desired depth with the at least two flexible arms flexing outward. Upon removal of the needle cannula from the skin, post-injection, the spring fully decompresses and the trigger housing moves distally along the shaft of the needle cannula past the distal tip. At this point the needle tip cap of the second leaf of the lock clip is released from contact with the needle cannula and flexes into the needle tip covering position. Typically, the force required to move the trigger housing and release the first leaf of the lock clip is less than the force to flex the two or more flexible arms so that the passive shielding mechanism is triggered within a short distance during injection
In one or more embodiments, the drug safety delivery device may further comprise structure for preventing triggering of the passive safety mechanism prior to administering the injection. This feature allows the device to be used to fill a syringe prior to injection without activating the passive shielding system. The anti-triggering structure is removed or disabled after filling of the syringe so that the passive shielding system becomes available for triggering during injection. In one or more embodiments, the anti-triggering structure may comprise a removable cap or sleeve which includes a rib to hold the first leaf of the lock clip in the engaged position and constrain proximal motion of the trigger housing during fill. Subsequent to filling the syringe, the cap is removed to allow proximal movement of the trigger housing and passive shielding upon injection. In certain embodiments, the anti-triggering component includes a removable fill cap which covers the needle cannula exposed at the distal end of the removable cap or sleeve prior to filling the syringe.
In an alternative embodiment, the anti-triggering component may comprise a bracket and pull-pin. The bracket (e.g., a “U” bracket) engages the drug delivery safety device in either side of the trigger housing to constrain movement of the trigger housing during the syringe filling process. The pull-pin facilitates removal of the bracket by pulling it to the side. This permits proximal movement of the trigger housing and passive shielding upon injection. This embodiment may also comprise a removable fill cap to cover the exposed needle cannula prior to filling the syringe. The fill cap may include a slot to accommodate fitting over the side pull-pin.
The user first removes the fill cap to fill the syringe which, due to the anti-triggering constraints of the removable sleeve or cap, can be done multiple times. When the user desires to administer an injection, the second component of the anti-triggering mechanism (e.g., sleeve/cap or bracket/pull pin) is removed from the drug delivery safety device to permit triggering of the passive safety feature during the injection. If the user intends to delay using the filled syringe for administering an injection, the fill cap can be re-applied until such time as injection is desired. In this case, the fill cap and second component are both removed prior to injection to allow triggering.
In any of these three aspects, it is to be understood that the needle tip may be exposed through the distal end of the housing of the locking mechanism or the housing may cover the needle tip provided that the needle tip is exposed through the distal end of the lock clip.
As used herein, the term “proximal,” “proximally-directed” and related terms with respect to the drug safety delivery device refer to a direction toward the needle hub or toward the syringe when the drug safety delivery device is attached to a syringe.
As used herein the term “distal, “distally-directed” and related terms with respect to the drug safety delivery device refer to a direction toward the needle tip or toward the patient's skin when the device is in use for administering an injection.
Before describing several exemplary embodiments, it is to be understood that the disclosure not limited to the details of construction or process steps set forth in the following description. The disclosure is capable of other embodiments and of being practiced or being carried out in various ways.
In general, provided are safety devices for passive shielding the distal tip of a needle cannula after it is used for injection. The safety devices include a collapsible or flexible structure directly or indirectly connecting the needle hub to a locking clip positioned at the distal end of the needle cannula. Initially, prior to use, the needle tip is exposed through the locking clip. The collapsible or flexible structure is longitudinally oriented between the needle hub and the locking clip, and surrounds, or runs adjacent to, the cannula. Prior to use of the safety device there is stored energy in the form of tension on the safety device which prevents the safety device from triggering and keeps the needle tip exposed for use. When the needle tip is inserted into the skin of the patient, the stored energy in the system is released and the safety device is activated or triggered. However, once activation occurs, the safety device does not shield the needle as long as the needle remains in the skin. This permits the user to continue to insert the needle to the desired depth. Only upon removal of the needle from the skin does the activated safety device automatically advance the locking clip forward to cover the tip of the needle, thereby automatically and passively preventing needle stick injury as soon as the injection is completed. In certain embodiments, the safety devices include additional components which allow for filling of a syringe, without triggering the passive safety mechanism, prior to injection.
These features can be achieved by several embodiments of the safety device. In addition to the advantages of automatic and immediate shielding of the used needle, these several embodiments provide the advantage of requiring less force against the patient's skin during injection to trigger the passive safety mechanism. The various aspects and embodiments also provide a passive mechanism for shielding a needle which activates during injection over a shorter stroke distance.
The Rotating Force Trigger
One embodiment, shown generally in
As illustrated in
An embodiment of rotating cam 18, configured for engagement with two slots opposite each other in body 16, is illustrated in more detail in
An anti-triggering component useable with the drug delivery safety device is also shown in
The Linear Distance Trigger
One embodiment, shown generally in
A body 64 fittingly engages needle hub 12. Body 64 has an inner cavity 66 with proximal end 68 and distal end 70, and a Y-clip 72 disposed in inner cavity 66. First arm 74 and second arms 76 of Y-clip 72 are held open by engagement, respectively, with first pocket 78 and second pocket 80 at the distal end of the inner cavity and by force of spring 62 which biases the first and second arms toward the “splayed” or “open” position. First and second arms 74, 76 of Y-clip 72 have angled surfaces 73, as shown in more detail in
Y-clip 72 is shown in more detail in
Front-End Trigger
One embodiment, shown generally in
An end-cap 122 connects the distal ends of the two flexible arms. Trigger housing 104 fits over end-cap 122. As shown in
Reference throughout this specification to “one embodiment,” “certain embodiments,” “various embodiments,” “one or more embodiments” or “an embodiment” means that a particular feature, structure, material, or characteristic described in connection with the embodiment is included in at least one embodiment of the disclosure. Thus, the appearances of the phrases such as “in one or more embodiments,” “in certain embodiments,” “in various embodiments,” “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily referring to the same embodiment of the disclosure. Furthermore, the particular features, structures, materials, or characteristics may be combined in any suitable manner in one or more embodiments.
Although the disclosure herein provided a description with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the disclosure. It will be apparent to those skilled in the art that various modifications and variations can be made to the present disclosure without departing from the spirit and scope thereof. Thus, it is intended that the present disclosure include modifications and variations that are within the scope of the appended claims and their equivalents.
This application is a divisional of U.S. patent application Ser. No. 17/007,071, filed on Aug. 31, 2020, now allowed, which is a divisional of U.S. patent application Ser. No. 15/837,469, filed on Dec. 11, 2017, issued as U.S. Pat. No. 10,814,073 on Oct. 27, 2020, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 62/433,297, filed Dec. 13, 2016, the disclosure of which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4795432 | Karczmer | Jan 1989 | A |
4804371 | Vailancourt | Feb 1989 | A |
4813940 | Parry | Mar 1989 | A |
4887998 | Martin | Dec 1989 | A |
4950250 | Haber et al. | Aug 1990 | A |
5013305 | Opie | May 1991 | A |
5395347 | Blecher et al. | Mar 1995 | A |
5591138 | Vaillancourt | Jan 1997 | A |
5688241 | Asbaghi | Nov 1997 | A |
5984899 | D'Alessio et al. | Nov 1999 | A |
RE36885 | Blecher et al. | Sep 2000 | E |
6884237 | Asbaghi | Apr 2005 | B2 |
6926697 | Malenchek | Aug 2005 | B2 |
7347838 | Kulli | Mar 2008 | B2 |
7361159 | Fiser et al. | Apr 2008 | B2 |
7513888 | Sircom et al. | Apr 2009 | B2 |
7811261 | Rubinstein et al. | Oct 2010 | B2 |
7922698 | Riesenberger et al. | Apr 2011 | B2 |
8062265 | Millerd | Nov 2011 | B2 |
8162882 | Rubinstein et al. | Apr 2012 | B2 |
8303541 | Chun | Nov 2012 | B2 |
8333738 | Millerd | Dec 2012 | B2 |
8439870 | Moyer et al. | May 2013 | B2 |
8496627 | Chelak et al. | Jul 2013 | B2 |
8617119 | Liversidge | Dec 2013 | B2 |
8636688 | Shaw | Jan 2014 | B2 |
8636703 | Foshee et al. | Jan 2014 | B2 |
8647307 | Gratwohl et al. | Feb 2014 | B2 |
8663129 | Allen et al. | Mar 2014 | B2 |
8747355 | Rubinstein et al. | Jun 2014 | B2 |
8827961 | Emmott et al. | Sep 2014 | B2 |
8968241 | Liversidge | Mar 2015 | B2 |
8979794 | Chevallier | Mar 2015 | B2 |
9050416 | Feret et al. | Jun 2015 | B2 |
9061106 | Roberts et al. | Jun 2015 | B2 |
9067024 | Roberts et al. | Jun 2015 | B2 |
9186466 | Zachek et al. | Nov 2015 | B2 |
9192724 | Fourt et al. | Nov 2015 | B2 |
9352099 | Roberts et al. | May 2016 | B2 |
9352100 | Ward et al. | May 2016 | B2 |
9352101 | Roberts et al. | May 2016 | B2 |
9370327 | Teoh | Jun 2016 | B2 |
9408632 | Erskine | Aug 2016 | B2 |
9445760 | Allen et al. | Sep 2016 | B2 |
9694140 | Rubinstein et al. | Jul 2017 | B2 |
9848810 | Allen et al. | Dec 2017 | B2 |
10022505 | Hu | Jul 2018 | B2 |
10814073 | Browka | Oct 2020 | B2 |
11642471 | Browka | May 2023 | B2 |
20030060774 | Woehr et al. | Mar 2003 | A1 |
20030181867 | Bressler et al. | Sep 2003 | A1 |
20040010227 | Riesenberger et al. | Jan 2004 | A1 |
20080221528 | Lanz | Sep 2008 | A1 |
20090299295 | Rubinstein et al. | Dec 2009 | A1 |
20100298770 | Rubinstein et al. | Nov 2010 | A1 |
20110288491 | Newman et al. | Nov 2011 | A1 |
20140135706 | Rubinstein et al. | May 2014 | A1 |
20140228772 | Ward et al. | Aug 2014 | A1 |
20140364803 | Rubinstein et al. | Dec 2014 | A1 |
20150094659 | Schraga | Apr 2015 | A1 |
20150182704 | Chevallier | Jul 2015 | A1 |
20150190580 | Imai et al. | Jul 2015 | A1 |
20150190586 | Takemoto | Jul 2015 | A1 |
20160095983 | Lewkonya et al. | Apr 2016 | A1 |
20180161523 | Sanders et al. | Jun 2018 | A1 |
Number | Date | Country |
---|---|---|
2803761 | Dec 2011 | CA |
103079610 | May 2013 | CN |
0750915 | Jan 1997 | EP |
2585146 | Mar 2017 | EP |
2007519474 | Jul 2007 | JP |
2013529973 | Jul 2013 | JP |
2014079375 | May 2014 | JP |
2013000081 | Mar 2013 | MX |
349289 | Jul 2017 | MX |
2009114777 | Sep 2009 | WO |
2012000833 | Jan 2012 | WO |
2012013587 | Feb 2012 | WO |
2013138549 | Sep 2013 | WO |
Entry |
---|
“PCT International Search Report and Written Opinion in PCT/US2017/065679 dated Jun. 13, 2018, 15 pages”. |
“PCT Invitation to Pay Additional Fees, and, Where Applicable, Protest Fee in PCT/US2017/065718 dated Apr. 9, 2018, 13 pages”. |
Number | Date | Country | |
---|---|---|---|
20230293824 A1 | Sep 2023 | US |
Number | Date | Country | |
---|---|---|---|
62433297 | Dec 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17007071 | Aug 2020 | US |
Child | 18129128 | US | |
Parent | 15837469 | Dec 2017 | US |
Child | 17007071 | US |